Neoadjuvant PD-1 blockade achieves encouraging clinical response in early-stage dMMR tumours
Findings from a small study support a non-surgical and tumour-agnostic approach with immunotherapy, but further research is needed
Promising early results for emiltatug ledadotin in heavily pretreated triple-negative breast cancer
Phase 1 trial data highlights preliminary efficacy and manageable safety of B7-H4–targeted antibody-drug conjugate in women receiving at least one prior topoisomerase-1 ADC
Shaping the future for young women facing breast cancer
Recent studies have refined current knowledge on how to better treat this patient population, taking care of their unique needs and expectations
Tailored use of chemotherapy may benefit some early-stage ER+/HER2– breast cancers
Results from two studies suggest that withholding chemotherapy for some patients may not impact efficacy, but an understanding of clinical and biological features is paramount
Adding adjuvant pertuzumab demonstrates prolonged survival benefit after 10+ years in HER2+ breast cancer
Final long-term overall survival data from APHINITY confirm the efficacy of dual HER2 blockade in patients with node-positive disease
TILs show value in predicting relapse risk in TNBC
Retrospective data suggest that patients with low baseline TILs and nodal involvement have poor prognosis despite achieving pathological complete response
Study findings refine the use of ctDNA to track resistance to endocrine therapy in advanced breast cancer
A timing window for testing ESR1 mutations in the blood was identified
Who benefits from immunotherapy for breast cancer?
Defining patients most likely to respond, a better understanding of the host–tumour immune axis and clinical trials for specific subtypes are key to extending success
Hortobagyi: “Patient involvement is central to advance research in breast cancer”
The 2025 ESMO Breast Cancer Awardee highlights that participation in clinical trials and the contribution of patient advocates is as relevant as technology to progress cancer care further
Will AI reshape breast cancer screening?
While AI tools have shown promise in reducing false positives and aiding radiologists, large prospective trials are now exploring how technology should be integrated in screening programmes